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Abstract: Development of drug resistance limits the efficacy of targeted therapies. Alternative 
approaches using different combinations of therapeutic agents to inhibit several pathways 
could be a more effective strategy for treating cancer. The effects of the approved epidermal 
growth factor receptor (EGFR)-tyrosine kinase inhibitor (gefitinib) or a multi-targeted kinase 
inhibitor (sorafenib) in combination with a histone deacetylase inhibitor (vorinostat) on cell 
proliferation, cell cycle distribution, apoptosis, and signaling pathway activation in human 
lung adenocarcinoma and hepatocarcinoma cells with wild-type EGFR and mutant KRAS were 
investigated. The effects of the synergistic drug combinations were also studied in human lung 
adenocarcinoma and hepatocarcinoma cells in vivo. The combination of gefitinib and vorinostat 
synergistically reduced cell growth and strongly induced apoptosis through inhibition of the 
insulin-like growth factor-1 receptor/protein kinase B (IGF-1R/AKT)-dependent signaling 
pathway. Moreover, the gefitinib and vorinostat combination strongly inhibited tumor growth 
in mice with lung adenocarcinoma or hepatocarcinoma tumor xenografts. In contrast, the 
combination of sorafenib and vorinostat did not inhibit cell proliferation compared to a single 
treatment and induced G2/M cell cycle arrest without apoptosis. The sorafenib and vorinostat 
combination sustained the IGF-1R-, AKT-, and mitogen-activated protein kinase-dependent 
signaling pathways. These results showed that there was synergistic cytotoxicity when vorinostat 
was combined with gefitinib for both lung adenocarcinoma and hepatocarcinoma with mutant 
KRAS in vitro and in vivo but that the combination of vorinostat with sorafenib did not show 
any benefit. These findings highlight the important role of the IGF-1R/AKT pathway in the 
resistance to targeted therapies and support the use of histone deacetylase inhibitors in combina-
tion with EGFR-tyrosine kinase inhibitors, especially for treating patients with mutant KRAS 
resistant to other treatments.
Keywords: targeted therapy, combined treatments, non-small cell lung cancer, hepatocarcinoma
Introduction
Although the use of new therapeutic agents has improved the treatment of cancer 
patients in recent years, the efficacy of targeted therapies is limited by the develop-
ment of drug resistance. Thus, the identification of alternative approaches that further 
disrupt tumor cell growth is essential, and these strategies could have a significant 
clinical impact. In particular, combinations of targeted agents could be exploited to 
inhibit more than one pathway and could be significantly more effective for achieving 
tumor regression than single therapeutic agents.
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Gefitinib and erlotinib are epidermal growth factor 
receptor (EGFR)-tyrosine kinase inhibitors (TKIs) that 
improve the survival of patients with EGFR-mutated non-
small cell lung cancer (NSCLC).1 For patients with EGFR 
wild-type tumors, first-line chemotherapy is still the standard 
of care.2 EGFR-TKIs are approved for use in second- and 
third-line treatments of advanced NSCLC or as a mainte-
nance therapy. However, the limited response to EGFR-TKIs 
observed in patients with wild-type EGFR NSCLC showed 
that there were intrinsic resistance mechanisms to EGFR-
TKIs including the KRAS mutation.3
Histone deacetylase (HDAC) inhibitors induce a range 
of anticancer effects, including tumor cell apoptosis, cell 
cycle arrest, differentiation, senescence, modulation of 
immune responses, and altered angiogenesis.4 Vorinostat 
and romidepsin are the most advanced HDAC inhibitors 
and are currently approved for treating cutaneous T-cell 
lymphomas.4–6 Belinostat is approved for the treatment of 
peripheral T-cell lymphoma, and panobinostat is approved 
for use in combination treatments for multiple myeloma.7,8 
Several studies support the use of HDAC inhibitors in 
combination with EGFR-TKIs in NSCLC cells to restore 
EGFR-TKI sensitivity.9–14 In this context, we recently showed 
the role of HDAC in the EGFR-TKI resistance of mutant 
KRAS adenocarcinoma.15,16
Sorafenib is a small-molecule TKI that targets vascu-
lar endothelial growth factor receptors, Raf kinases, and 
platelet-derived growth factor receptor. It was the first 
inhibitor to produce a survival benefit for advanced hepato-
cellular carcinoma (HCC).17 However, the majority of HCC 
patients do not respond to sorafenib, and most, if not all, 
patients who initially respond to sorafenib develop tumor 
resistance after a few months of treatment.18 Preclinical 
studies have also shown that combining HDAC inhibitors 
with sorafenib can have antiproliferative, antiangiogenic, 
and proapoptotic effects on epithelial tumor cells including 
HCC cells.19–22
Based on these data, we hypothesized that a combi-
nation treatment with HDAC inhibitors and TKIs could 
overcome the intrinsic resistance of epithelial tumor cells 
to TKI, and lead to more effective treatment, especially for 
both HCC and NSCLC with wild-type EGFR and mutant 
KRAS. Therefore, we investigated the effects of combina-
tions of the HDAC inhibitor vorinostat with either multi-
targeted kinase inhibitor sorafenib or EGFR-TKI gefitinib 
on antiproliferative and survival pathways in NSCLC and 
HCC cells with wild-type EGFR and mutant KRAS in vitro 
and in vivo.
Materials and methods
Cell lines
NSCLC (A549, H1299, H358, H322, and H1719) and HCC 
(HepG2, Hep3B, HuH7, Hep40, and PLC/PRF5) cell lines 
were obtained from the American Type Culture Collection 
(Manassas, VA, USA), and further authentication was not 
performed. These cells were maintained in RPMI 1640 
(Gibco, Cergy Pontoise, France) supplemented with 10% 
fetal bovine serum in a humidified atmosphere with 5% CO2. 
We routinely carried out morphology checks on all cell lines, 
and we only passaged the cell lines for 3 months. All cell 
lines were routinely tested for the presence of mycoplasma 
(MycoAlert® Mycoplasma Detection Kit, Lonza, France).
Drugs
Sorafenib tosylate, vorinostat (SAHA, MK0683), and 
linsitinib (OSI-906) were obtained from Selleckchem 
(Munich, Germany). Gefitinib (ZD1839) was provided by 
AstraZeneca (Paris, France). All drugs were dissolved in 
sterile dimethyl sulfoxide at 10 mmol/L stock solution.
Cell proliferation assay
Cells that were growing exponentially were seeded in 
96-well plates and exposed to serial dilutions of gefitinib, 
sorafenib, and vorinostat in regular growth medium contain-
ing 10% fetal bovine serum for 96 hours. Cell proliferation 
was measured with the 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide assay. Growth inhibition was 
expressed as the percentage of surviving drug-treated cells 
compared to untreated control cells. The drug concentrations 
required to inhibit cell growth by 50% (IC50) were determined 
by interpolation from the dose to response curves. Combina-
tions of treatments were performed in 96-well plates using 
serial dilutions ranging from 0 to IC50 (0; 0.2 IC50; 0.4 IC50; 0.6 
IC50; 0.8 IC50; and IC50). The combination effect of treatments 
was evaluated using the method described by Chou et al23 
using the CompuSyn program (ComboSyn Inc., Paramus, 
NJ, USA). Interactions between drugs were expressed as 
the combination index (CI) determined with CompuSyn 
software: CI 0.9 represented synergistic cytotoxicity; 0.9 
CI 1.1 represented additive cytotoxicity; and CI 1.1 
represented antagonistic cytotoxicity. The dose reduction 
index (DRI) values represented the amount that the dose 
of each drug in a synergistic combination could be reduced 
to achieve a given effect level compared to a dose of each 
drug alone. Fa–CI and Fa–DRI plots were built and showed 
CI or DRI on the y-axis as a function of the effect level (Fa) 
on the x-axis.
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Cell cycle analysis
Cells were harvested, pooled, fixed with 70% ethanol, and 
incubated in phosphate-buffered saline (PBS) at 37nC for 
30 minutes before being stained with 20 Mg/mL propidium 
iodide. The percentage of cells in specific cell cycle phases 
(G0/G1, S, and G2/M) was determined using a flow cytometer 
(Accuri C6, Becton Dickinson, Le Pont-de-Claix, France).
Apoptosis assays
The morphological changes related to apoptosis were 
assessed by fluorescence microscopy after staining the cells 
with Hoechst 33342 (5 Mg/mL, Sigma). The percentage of 
apoptotic cells was scored after counting at least 500 cells. 
Active caspase-3 and poly(adenosine diphosphate ribose) 
polymerase (PARP) cleavage were detected with immunob-
lotting. Apoptotic cells with hypodiploid DNA staining were 
counted in the “sub-G1” peak using flow cytometry.
Immunoblotting
Cells were lysed and immunoblotting was performed 
as previously described15,16 using antibodies against 
cleaved caspase-3 (Asp175), actin, phospho-EGFR-Y1068, 
EGFR, phospho-protein kinase B (AKT)-S473, pan-AKT, 
phospho-signal transducer and activator of transcription 
(STAT)3-Y705, STAT3, phospho-extracellular signal-
regulated kinase (ERK)1/2-T202/Y204, and ERK1/2 (Cell 
Signaling Technology, St Quentin en Yvelines, France), 
PARP (SantaCruz Biotechnology, Heidelberg, Germany), 
acetylated A-tubulin and A-tubulin (Abcam, Paris, France), 
and p21WAF1 (Merck Millipore, Molsheim, France).
In vivo models
The effect of the combination of gefitinib and vorinostat was 
measured in established subcutaneous tumor-bearing mice. 
All the animal experiments were performed in agreement 
with the European Economic Community guidelines and the 
“Principles of Laboratory Animal Care” (NIH publication 
N 86-23 revised 1985). Animal experiment studies were 
approved through institutional guidelines and by the European 
Community for the use of experimental animals (authorization 
to experiment 2015031115126706). Female NMRI nude mice 
(6–8 weeks old, Janvier, Le Genest-Saint Isle, France) were 
injected subcutaneously in the flank with 20r106 H358 cells 
suspended in PBS or 5r106 PLC/PRF5 cells suspended in 50% 
Matrigel (BD Biosciences, San Jose, CA, USA). Tumor size 
was measured twice a week using a caliper, and the tumor 
volume was calculated as follows: length r (width)2 r0.4. 
When tumors of ^250 mm3 in size were detected, the mice 
were randomized into four groups (8–11 mice per group) and 
were orally treated with 5 (H358) or 50 mg/kg/day (PLC/
PRF5) gefitinib and/or vorinostat (100 mg/kg/day) for either 
5 (H358) or 3 (PLC/PRF5) days a week. Control mice received 
an oral vehicle (Tween/dimethyl sulfoxide). Mice bearing 
tumors 2 cm3 were euthanized immediately. At the end of 
the experiment, tumor samples were excised and frozen for 
Western blot and immunohistochemical analyses.
Immunohistochemical staining
Tumor sections of a 7-Mm thickness were fixed with 4% 
paraformaldehyde and incubated overnight at 4nC with anti-
bodies. Immunohistochemical staining of Ki67 and cleaved 
caspase-3 was performed as previously described.15 Terminal 
deoxynucleotidyl transferase dUTP nick end labeling was 
performed according to the manufacturer’s instructions 
(Roche Diagnostics, Mannheim, Germany).
Statistical analysis
A comparison of mean values was performed using the 
Mann–Whitney U-test or an analysis of variance test. 
A P0.05 was considered to be significant. Univariate 
analyses were conducted using the Kaplan–Meier method and 
the log-rank test for tumor-bearing mice. All analyses were 
performed using Statview 4.1 software (Abacus Concept, 
Berkeley, CA, USA).
Results
Single-drug inhibition of proliferation in 
NSCLC and HCC cell lines
We first evaluated the ability of gefitinib, sorafenib, or 
vorinostat to inhibit growth in human NSCLC (A549, 
H1299, H358, H1719, and H322) and HCC (Hep3B, Huh7, 
HepG2, Hep40, and PLC/PRF5) cell lines harboring wild-
type EGFR, and wild-type or mutant KRAS (Table 1). Cancer 
cells were treated with increasing concentrations of gefitinib, 
sorafenib, or vorinostat. There was a wide range of gefitinib 
sensitivity for NSCLC cell lines, and HCC cells were resistant 
to gefitinib. The IC50 concentrations for sorafenib had the 
same range in NSCLC and HCC cells. The IC50 concentra-
tions indicated that the HCC cell lines were slightly more 
sensitive to vorinostat than the NSCLC cell lines.
Effects of drug combinations on NSCLC 
and HCC cell growth
H358, A549, and PLC/PRF5 mutant KRAS cell lines were 
selected to be treated with combinations of vorinostat and 
either gefitinib or sorafenib. Compared to single treatments, 
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Table 1 The sensitivity of human NSCLC and HCC cell lines to gefitinib, sorafenib, and vorinostat
Cell lines Origin EGFR status KRAS status IC50 (*mol/L)
Gefitinib Sorafenib Vorinostat
A549 NSCLC wt mut 12.8 4.8 3.0
H1299 NSCLC wt wt 28.7 4.9 3.9
H358 NSCLC wt mut 1.3 4.7 3.0
H322 NSCLC wt wt (amplification) 1.5 6.9 3.2
H1719 NSCLC wt wt 6.0
Hep3B HCC wt wt 12.5 4.2 2.6
Huh7 HCC wt wt 14.5 3.0 1.6
HepG2 HCC wt mut 9.6 2.9 2.0
PLC/PRF5 HCC wt mut 9.4 4.7 2.4
Note: The drug concentrations required to inhibit cell growth by 50% were determined by interpolation from the dose to response curves.
Abbreviations: HCC, hepatocellular carcinoma; mut, mutant; NSCLC, non-small cell cancer; wt, wild type.
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Figure 1 (Continued)
H358 and PLC/PRF5 cells treated with increasing concen-
trations of gefitinib and vorinostat exhibited significantly 
decreased viability (Figure 1A and B). This effect was 
confirmed in A549 cells (Figure 1) and in wild-type KRAS 
H322 cells (Supplementary material S1), which harbored 
an amplification of KRAS.24 The CI values measuring the 
degree of drug interaction indicated a synergistic interac-
tion between gefitinib and vorinostat (Figure 1A and B, 
Supplementary material S2). Synergism was confirmed 
by measuring how many folds the dose of each drug in a 
synergistic combination may be reduced using the DRI. In 
contrast, the effect of the combination of vorinostat with 
sorafenib was not significantly different from the effect of 
each drug alone for each of the concentrations studied in 
H358, PLC/PRF5, and A549 cells (Figure 1C, D, and F) and 
in wild-type KRAS cell lines (Supplementary material S1). 
Vorinostat and sorafenib treatment resulted in an antago-
nistic interaction in KRAS mutant cells and H322 cells 
(Figure 1C and D, Supplementary material S2). Taken 
together, these findings indicate that vorinostat synergized 
with gefitinib, but not with sorafenib, especially in the 
mutant or amplified KRAS cells.
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Figure 1 Antitumor effects of drug combinations in mutant KRAS cells.
Notes: H358 (A, C) and PLC/PRF5 (B, D) cells were treated for 96 hours with increasing concentrations of gefitinib and vorinostat (A, B), or sorafenib and vorinostat 
(C, D). A549 cells were treated with 3 Mmol/L gefitinib and/or 2 Mmol/L vorinostat and/or 3 Mmol/L sorafenib as indicated (E, F). Cell viability was measured by the MTT 
assay. Values are the means o standard deviation of three independent experiments. *P0.05 compared to cells treated with each drug alone.
Abbreviations: CI, combination index; DRI, dose reduction index; Fa, fraction affected.
Effects of drug combinations on NSCLC 
and HCC cell cycle distribution
The effect of vorinostat combined with either gefitinib or 
sorafenib on cell cycle distribution was analyzed by flow 
cytometry in H358 and PLC/PRF5 cells (Supplementary 
material S3). None of the three single agent treatments 
resulted in a marked change in the cell cycle distribution 
(Figure 2). However, the combination of gefitinib with 
vorinostat induced a strong and statistically significant 
accumulation of sub-G1 cells together with a decrease in the 
G0/G1 and/or G2/M phases (Figure 2A and B). In contrast, 
the combination of sorafenib and vorinostat induced a strong 
accumulation of cells in the G2/M phases in H358 cells 
(Figure 2C) and had no significant effect in PLC/PRF5 cells 
(Figure 2D). These cell cycle aberrations strongly suggest 
that vorinostat, when combined with gefitinib, “induced” 
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Figure 2 Effects of drug combinations on cell cycle distribution and apoptosis in mutant KRAS cells.
Notes: H358, A549, and PLC/PRF5 cells were treated for 96 h with gefitinib (H358: 0.2 Mmol/L, A549 and PLC/PRF5: 3 Mmol/L) and/or vorinostat (2 Mmol/L) (A, B, E), or 
with sorafenib (3 Mmol/L) and/or vorinostat (2 Mmol/L) (C, D, F). (A–D) The cell cycle distribution was analyzed using flow cytometry. DNA was stained with propidium 
iodide. The histograms represent the percentage of cells in each cell cycle phase (mean o standard deviation of three independent experiments). *P0.05; **P0.01; 
***P0.001 compared to control or to cells treated with each drug alone. (E, F) Caspase-3 and PARP cleavage were evaluated using Western blotting.
Abbreviation: PARP, poly(adenosine diphosphate ribose) polymerase.
apoptotic in both cell lines, whereas when combined with 
sorafenib induced a G2/M arrest.
Apoptotic effects of drug combinations 
in NSCLC and HCC cell lines
We further investigated the apoptotic effects of vorinostat 
combined with the TKIs with Western blots. Similar to the 
increase in the apoptotic sub-G1 population, a combination of 
gefitinib with vorinostat was more effective than each drug alone 
for inducing caspase-3 and PARP cleavage in KRAS mutant 
cells (Figure 2E). This combination also strongly induced apop-
tosis in amplified KRAS H322 cells and wild-type KRAS H1719 
cells (Supplementary material S3). In contrast, the combination 
of vorinostat with sorafenib did not enhance the level of cleaved 
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caspase-3 and PARP compared to single treatments in all the 
cells that were tested (Figure 2F, Supplementary material S3). 
Taken together, these findings indicate that the synergistic inter-
action between gefitinib and vorinostat is associated with the 
induction of apoptosis. In contrast, the combination of vorinostat 
and sorafenib failed to induce apoptosis, which showed that 
there was no beneficial interaction.
Effects of drug combinations on signaling 
pathways in NSCLC and HCC cell lines
We measured the activity of the combined treatments on 
key intracellular pathways in cell survival and proliferation. 
As expected, vorinostat enhanced the acetylation of A-tubulin 
and induced the expression of p21WAF1. The combination of 
vorinostat and gefitinib slightly enhanced A-tubulin acety-
lation but attenuated the induction of p21WAF1 by vorinostat 
(Figure 3A). These effects were also observed in wild-type 
KRAS cells (Supplementary material S3). Sorafenib alone 
and in combination with vorinostat enhanced the acetylation 
of A-tubulin in an additive manner but markedly inhibited 
p21WAF1 and its induction by vorinostat (Figure 3B).
Gefitinib alone markedly inhibited phospho-EGFR 
(p-EGFR) but enhanced or maintained phosphor-insulin-
like growth factor-1 receptor (p-IGF-1R) in resistant KRAS 
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mutant cells (Figure 3A). Vorinostat alone had no significant 
effect on the activation of EGFR or IGF-1R. When gefitinib 
was combined with vorinostat, a marked reduction of 
p-IGF-1R, except in H358 cells, was observed compared to 
each drug alone in the KRAS mutant cell lines (Figure 3A). 
No effect of a single or combined treatment was observed in 
EGFR or IGF-1R levels. Downstream of these receptors, we 
showed that gefitinib or vorinostat alone had no significant 
effect on p-AKT, p-ERK, and p-STAT3. The exception 
was H358 cells in which p-AKT and p-ERK were slightly 
enhanced, and this effect was previously observed.25 The drug 
combination markedly reduced p-AKT in the three KRAS 
mutant cell lines (Figure 3A) in correlation with apoptosis 
induction.
Sorafenib induced a paradoxical increase of p-IGF-1R 
and p-ERK (Figure 3B). The combination of sorafenib with 
vorinostat maintained or enhanced p-EGFR, p-IGF-1R, 
p-AKT, and p-ERK in comparison with each drug alone 
and in correlation with the absence of apoptosis, which sug-
gested that sorafenib induced survival pathways that were 
not inhibited by vorinostat.
Moreover, the inhibition of IGF-1R using an IGF-1R-
TKI (linsitinib) decreased the gefitinib-induced activation of 
AKT (Figure 3C) and restored apoptosis in the three KRAS 
mutant cell lines (Figure 3D). These data strongly suggest 
that the IGF-1R-dependent AKT signaling pathway medi-
ated resistance to gefitinib in cells with mutant KRAS and is 
controlled by vorinostat.
Together, these findings show that vorinostat combined 
with gefitinib potently repressed IGF-1R/AKT-dependent 
survival signaling in the NSCLC and HCC KRAS mutant 
cells, but a similar effect was not observed when vorinostat 
was combined with sorafenib.
Antitumor efficacy of a gefitinib and 
vorinostat combination in NSCLC and 
HCC cells in vivo
Because the gefitinib and vorinostat combination showed 
synergistic effects in vitro, we examined their in vivo coop-
erativity using H358 or PLC/PRF5 subcutaneous xenografts 
in mice. Oral treatments with gefitinib (5 mg/kg) and vor-
inostat (100 mg/kg) were well-tolerated, and no significant 
weight loss was observed in the H358 tumor-bearing mice 
(Figure 4A). Single-drug treatment did not inhibit H358 
tumor growth and weight compared with the control group. 
The combination of gefitinib and vorinostat had a strong 
significant inhibitory effect on both H358 tumor growth 
and weight (Figure 4A). This combination of treatments 
reduced the tumor volume more effectively than each drug 
alone, and the growth inhibition index calculations showed 
synergistic effects of the gefitinib/vorinostat combination 
in H358 tumors (Table 2). This effect was also observed 
in the PLC/PRF5 xenograft model. According to the IC50 
concentrations (Table 1), we used 50 mg/kg gefitinib for 
treating PLC/PRF5 tumor-bearing mice in combination with 
100 mg/kg vorinostat. Because this dose of gefitinib induced 
8%–12% weight loss 1 week after beginning the treatment 
in PLC/PRF5 tumor-bearing mice (not shown), we reduced 
the frequency of treatment administration to three times a 
week. This adaptation was better tolerated and was contin-
ued until the end of the experiment (Figure 4B). Gefitinib 
alone or in combination with vorinostat inhibited PLC/PRF5 
tumor growth with a synergistic interaction compared with 
the control group (Figure 4B, Table 2). In addition, because 
of the rapid growth of PLC/PRF5 tumors and the reduced 
frequency of the treatment, some animals in the control and 
vorinostat-treated groups presented rapidly growing tumors 
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Figure 3 Effects of drug combinations on signaling pathways in mutant KRAS cells.
Notes: H358, A549, and PLC/PRF5 cells were treated for 96 hours with gefitinib (H358: 0.2 Mmol/L, A549 and PLC/PRF5: 3 Mmol/L), sorafenib (3 Mmol/L), vorinostat 
(2 Mmol/L), OSI-906 (H358: 1 Mmol/L, A549 and PLC/PRF5: 3 Mmol/L), alone or combined as indicated. (A, B, D) Total cell lysates were collected and subjected to Western 
blotting. (C) The percentage of apoptosis was scored and expressed as the mean o standard deviation.
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that reached 2 cm3. These animals were removed from the 
experiment for ethical reasons, which reduced the popula-
tion of these two groups. This phenomenon significantly 
decreased when the mice received gefitinib or gefitinib/
vorinostat, which highlighted the benefit of these two treat-
ments (Figure 4C). This effect was not observed in H358 
tumor-bearing mice because of the growth rate of H358 
tumors and the frequency of the treatments.
Intratumoral biomarkers were assessed with Western 
blot and immunohistochemical analyses. Consistent with 
the in vitro data, vorinostat enhanced the acetylation of 
tubulin and histone H4, and the combined treatments 
decreased p-AKT and slightly enhanced active-caspase 
three levels (Figure 4D). Ki67 immunostaining showed 
that the gefitinib and vorinostat combination significantly 
decreased cell proliferation by approximately twofold in 
H358 tumors and 1.5-fold in PLC/PRF5 tumors compared 
to the control- or single-treatment groups (Figure 4E). 
Active-caspase-3 and terminal deoxynucleotidyl transferase 
dUTP nick end labeling in the tumors showed that single 
and combined treatments enhanced apoptosis compared to 
the control group (Supplementary material S4). Thus, the 
gefitinib and vorinostat combined treatments enhanced the 
antitumor activity of each drug in vivo.
Discussion
Although the development of selective molecular targeted 
therapies has led to advances in cancer treatment, several 
relevant issues for the optimal and effective use of targeted 
therapies remain unsolved. Clinical responses to a single 
agent EGFR-TKI or the multi-kinase inhibitor sorafenib 
have rarely been observed in NSCLC and HCC patients, 
respectively,1,17 and these patients will eventually develop 
resistance.2,18,26 There is an urgent need for the identification 
of alternative therapeutic strategies. In this respect, combina-
tions of targeted drugs could be key factors for increasing 
therapeutic efficacy, especially in patients with mutant KRAS 
NSCLC or HCC.
Despite the demonstrated benefits of EGFR-TKI in 
NSCLC patients with EGFR-activating mutations, not all 
patients with NSCLC respond to treatment and they eventu-
ally develop resistance.1,2 Unlike NSCLC, very few studies 
have shown the effects of single agent EGFR-TKI treatment 
in HCC cells.27–29 The clinical efficacy of EGFR inhibitors as 
single agents in HCC is modest.30 Likewise, a limited clinical 
benefit was observed with HDAC inhibitors for patients with 
solid tumors, including NSCLC and HCC.11 In lung cancer, 
phase II trials of vorinostat showed encouraging results.31 
However, the subsequent phase III randomized trial failed to 
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Figure 4 Effects of the gefitinib and vorinostat combination on the growth of H358 or PLC/PRF5 xenografts.
Notes: H358 and PLC/PRF5 cells were grown as subcutaneous tumor xenografts in nude mice. After the tumors were established, the mice were treated with vehicle, 
gefitinib (5 mg/kg H358 or 50 mg/kg PLC/PRF5), vorinostat (100 mg/kg), or both for 30–35 days. (A, B) The means of body weight and tumor weight at sacrifice and the 
means of tumor volume o SEM at the given time points in H358 (A) or PLC/PRF5 (B) xenograft models. *P0.05; **P0.01; ***P0.001 compared to the control group; 
#P0.05 compared to the single treatment groups. Treatment groups included 8–11 mice, except for the PLC/PRF5 xenograft model in which the vehicle and vorinostat-
treated groups included only four to six mice (♮) because of euthanasia due to tumor size. (C) Tumor size-related death was calculated from the date of the beginning of 
treatment to the last day of the experiment or tumor size-related death for the PLC/PRF5 tumor-bearing mice. P log-rank 0.0095. (D) Effect of gefitinib and vorinostat on 
acetylated-tubulin, acetylated-histone H4, p-AKT and active caspase-3 in H358- (tumors 1–8), and PLC/PRF5-xenograft tumors (tumors 9–16) assessed by Western blotting 
(two mice per condition). (E) Ki67 nuclear protein detected through immunostaining on frozen tumor sections from mice that were treated as indicated. The Ki67 level 
was determined after counting positive-stained cells in ten randomly selected fields per slide in the tumor sections, and the results are expressed as the mean o standard 
deviation and as the rate of staining in the vehicle-treated group (three to six mice per group). *P0.05; ***P0.001 compared to the control group; #P0.05 compared to 
the single treatment groups.
demonstrate improvements in the response rate and survival 
with vorinostat.11
The results demonstrated that in comparison to single 
agents, the combined inhibition of EGFR and HDAC pro-
vided a stronger inhibition of cell growth and induction of 
cell death in NSCLC and HCC cell lines. These effects were 
demonstrated in vitro and in vivo. We observed that the 
synergistic interaction of gefitinib and vorinostat triggered 
apoptosis in NSCLC and HCC cell lines with wild-type 
EGFR and mutant KRAS and that these therapies showed 
inhibition of NSCLC and HCC tumor growth in vivo. Other 
preclinical studies reported enhanced efficacy of EGFR and 
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Table 2 Synergistic indexes of combination treatment with gefitinib and vorinostat in vivo
Xenografts Gefitinib Vorinostat Gefitinib  vorinostat Indexd
Conc (mg/kg) MGIa P-valuee Conc (mg/kg) MGI P-valuee Expectedb Observedc P-valuee
H358 5 0.87 ns 100 0.80 ns 0.69 0.34 0.01 2.02
PLC/PRF5 50 0.65 0.0193 100 1.02 ns 0.67 0.46 0.0002 1.46
Notes: Growth inhibition rate were calculated at the end of the experiment on established subcutaneous H358 or PLC/PRF5 tumor nodules in athymic nude mice treated 
with indicated concentrations of gefitinib, vorinostat, or their combination. aMean growth inhibition rate  growth rate of treated group/growth rate of untreated group 
bGrowth inhibition rate of gefitinib r growth rate of vorinostat. cGrowth inhibition rate of combined treatment on gefitinib and vorinostat treatments. dCalculated by dividing 
the expected growth inhibition rate by the observed growth inhibition rate. An index 1.1 indicates synergistic effect, between 0.9 and 1.1 indicates additive effect, and 0.9 
indicated less than additive effect. eP-value was calculated by bilateral t-test compared to control treatment or to gefitinib or vorinostat alone (P0.5).
Abbreviations: MGI, mean growth inhibition; ns, nonsignificant.
HDAC co-inhibition in NSCLC cells9,12–16,32 and in head 
and neck carcinoma cells.33 Interestingly, we were not able 
to find reports on the combined effects of EGFR-TKI and 
HDAC inhibitors in HCC. The sub-optimal doses of gefi-
tinib and vorinostat that were used in H358 tumor-bearing 
mice, as well as the lower frequency of administration used 
in PLC/PRF5 tumor-bearing mice, were not associated 
with any documented side effects, and no signs of toxicity 
were observed in the co-treated animals. Few clinical trials 
investigated EGFR-TKI and HDAC inhibitor combination in 
NSCLC patients, but they did not improve the outcomes in 
unselected patients or in patients with EGFR mutations.34–36 
In contrast, the results strongly support the value of 
associating HDAC inhibitors with EGFR-TKI treatments in 
drug-resistant mutant KRAS patients.
The mechanistic analysis suggested that the synergism 
between gefitinib and vorinostat involved the inhibition 
of the IGF-1R and AKT pro-survival pathways and that 
apoptosis was activated in both NSCLC and HCC cells 
with mutant or amplified KRAS.24 The combined treatment 
maintained p-IGF-1R only in H358 cells but still inhibited 
p-AKT, which suggested that it was acting downstream 
of the IGF-1R via a mechanism that still needed to be 
elucidated. Accordingly, IGF-1R was involved in resis-
tance to EGFR-TKI in mutant KRAS NSCLC cells.16,25,37 
Moreover, acetylation mechanisms regulated IGF-1R- and 
PI3K/AKT signaling,38,39 and the combination of an HDAC 
inhibitor with an EGFR-TKI inhibited AKT signaling in 
lung and head and neck cancer cells.9,14,16,33 It has also been 
reported that HDAC and EGFR co-inhibition modulated 
ErbB receptor levels but that these effects were indepen-
dent of the EGFR or KRAS status.9,33 We also observed 
that gefitinib slightly downregulated vorinostat-induced 
p21WAF1 expression. P21WAF1 is a cyclin-dependent kinase 
inhibitor that played an important role in the regulation of 
the G1/S cell cycle and that may have protected cells from 
undergoing apoptosis.40 Therefore, the apoptotic effects of 
a gefitinib and vorinostat combination may have occurred 
through p21WAF1 inhibition.
Sorafenib is the standard of care for the treatment of 
advanced HCC.17 However, its clinical benefits remain 
modest and most often consist of temporary tumor 
stabilization.18 In NSCLC, sorafenib did not show clinical 
activity in a randomized phase III trial in NSCLC patients 
with a KRAS mutation.41 The first completed prospective, 
biopsy-mandated, biomarker-based, adaptively random-
ized study in pretreated lung cancer patients (Biomarker-
integrated Approaches of Targeted Therapy for Lung Cancer 
Elimination, BATTLE trial) reported a benefit of sorafenib 
in patients with mutated or wild-type KRAS.42
Preclinical studies have demonstrated antiproliferative, 
antiangiogenic, and proapoptotic effects from combining 
HDAC inhibitors with sorafenib in epithelial tumor cells,19–21 
including HCC cells.22 Several phase I studies investigated 
HDAC inhibitors in combination with sorafenib, and these 
studies either support future clinical development of an 
entinostat/sorafenib combination in patients with advanced 
solid tumors43 or show that the combined sorafenib and 
vorinostat treatment was not tolerated and had no confirmed 
response in patients with renal cell carcinoma and NSCLC.44 
We observed that an antagonistic combination of vorinostat 
with sorafenib failed to enhance apoptosis in both NSCLC 
and HCC cells. This combination of treatments induced G2/M 
cell cycle arrest, maintained IGF-1R, AKT, and ERK activa-
tion, but failed to induce apoptosis. Accordingly, IGF-1R/
AKT pathway inhibition has been shown to improve the 
efficacy of molecular-targeted therapies such as sunitinib for 
HCC.45 Although sorafenib targets B-Raf and C-Raf in the 
ERK signaling pathway, we observed that sorafenib did not 
inhibit ERK phosphorylation in cells with mutant KRAS, as 
previously shown.46 In addition, the sorafenib and vorinostat 
combination strongly downregulated p21WAF1 expression. 
Accordingly, the p21WAF1 knockdown has been shown 
to decrease the anti-proliferative activity of vorinostat.47 
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The antagonistic effects of a vorinostat and sorafenib com-
bination may result from the inhibition of the expression of 
the tumor-suppressor gene p21WAF1. In addition, other cyclin-
dependent kinases may also be involved. After labeling the 
senescent cells using acid B-galactosidase staining, we did not 
observe any significant signals in response to a sorafenib and 
vorinostat combination (data not shown), which suggested 
that this treatment did not induce senescence. Interestingly, 
autophagy played a compensatory role during treatment with 
sorafenib, vorinostat, or their combination in HCC cells.48 
This result could explain the absence of apoptosis and should 
be investigated further.
Conclusion
In summary, HDAC inhibitors have the potential to restore 
tumor cell sensitivity to EGFR-TKIs and dramatically reduce 
the concentration of EGFR-TKI necessary to induce cell death 
in mutant KRAS NSCLC and HCC cells in vitro and in vivo 
through IGF-1R-dependent AKT signaling downregulation. In 
contrast, sorafenib exerts an antagonistic effect when combined 
with vorinostat both in NSCLC and HCC cell lines through 
IGF-1R-dependent AKT signaling activation. Many clinical 
trials have been completed without prospectively evaluating or 
targeting the specific subpopulation of drug-resistant patients; 
the addition of a new agent could be clinically effective when 
based on preclinical data. The observations, which demon-
strated the synergistic antitumor activity of gefitinib combined 
with vorinostat, should be considered when designing future 
clinical trials based on the association of these inhibitors in 
NSCLC or HCC patients with mutant KRAS.
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